Boston Scientific Corporation $BSX Shares Bought by Arrowstreet Capital Limited Partnership

Arrowstreet Capital Limited Partnership grew its position in Boston Scientific Corporation (NYSE:BSX) by 28.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,367,398 shares of the medical equipment provider’s stock after purchasing an additional 1,837,480 shares during the quarter. Arrowstreet Capital Limited Partnership owned about 0.56% of Boston Scientific worth $816,909,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Steph & Co. purchased a new stake in Boston Scientific in the third quarter valued at about $25,000. Financial Consulate Inc. acquired a new position in shares of Boston Scientific during the third quarter valued at about $25,000. Murphy & Mullick Capital Management Corp increased its holdings in shares of Boston Scientific by 200.0% during the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 170 shares in the last quarter. FWL Investment Management LLC purchased a new position in shares of Boston Scientific in the 2nd quarter valued at approximately $26,000. Finally, United Community Bank boosted its stake in Boston Scientific by 115.7% in the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 147 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Insider Transactions at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. Citigroup dropped their target price on shares of Boston Scientific from $102.00 to $94.00 and set a “buy” rating on the stock in a research report on Wednesday. JPMorgan Chase & Co. decreased their price target on shares of Boston Scientific from $135.00 to $100.00 and set an “overweight” rating for the company in a report on Thursday, February 5th. UBS Group lowered their price objective on shares of Boston Scientific from $140.00 to $120.00 and set a “buy” rating for the company in a research note on Thursday, February 5th. Mizuho cut their target price on Boston Scientific from $140.00 to $115.00 and set an “outperform” rating on the stock in a research report on Thursday, February 5th. Finally, Weiss Ratings lowered Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Wednesday, February 4th. Two analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $108.00.

Boston Scientific Stock Performance

BSX opened at $68.62 on Friday. Boston Scientific Corporation has a 1 year low of $67.56 and a 1 year high of $109.50. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. The firm has a fifty day moving average price of $82.98 and a 200 day moving average price of $93.64. The stock has a market cap of $101.82 billion, a P/E ratio of 35.37, a P/E/G ratio of 0.97 and a beta of 0.69.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The business had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. During the same period in the prior year, the company posted $0.70 EPS. The company’s revenue for the quarter was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Equities research analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Citigroup lowered its price target for BSX from $102 to $94 but kept a Buy rating, which still implies significant upside from current levels and signals some analyst confidence in the company’s fundamentals. Article Title
• Neutral Sentiment: Zacks published a market‑move note explaining the stock’s drop today, providing context on trading and investor reaction rather than new company fundamentals. Why Boston Scientific (BSX) Dipped
• Neutral Sentiment: Multiple law firms are circulating investor notices and deadline reminders (lead‑plaintiff motions due May 4, 2026). These solicitations increase headline volume and may drive short‑term selling even before any case merits are resolved. Example notices: Pomerantz and Robbins Geller. Pomerantz Investor Alert Robbins Geller Notice
• Negative Sentiment: A filed securities class action alleges executives misrepresented U.S. electrophysiology procedure volumes — if these allegations gain traction they could lead to regulatory scrutiny, litigation costs or reputational damage. Lawsuit Allegations
• Negative Sentiment: Unusually heavy put‑option buying has been reported, suggesting some traders are positioning for further near‑term downside or hedging against headline risk. That activity can amplify intraday declines. Put Options Activity

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.